-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
5 views
ACHV's cytisinicline shows best-in-class efficacy and safety for smoking cessation, supported by strong clinical data and recent NDA submission. The target market is large, with millions seeking smoking cessation annually. Recent financing extends ACHV's cash runway through FDA approval, but further capital will be needed for commercialization.
